Personalized glycemic response led digital therapeutics program improves time in range in a period of 14 days

• Published in: International journal of diabetes in developing countries Vol. 43; no. 3; pp. 425 - 432
• Main Authors: Verma, Ritika, Bhardwaj, Shefali, Lathia, Tejal, Kalra, Sanjay, Ranadive, Ruchira, Tanna, Snehal, Padsalge, Mahesh, Juneja, Archana, Samundra, Kirti, Thakkar, Piya Ballani, Jain, Vandana, Kini, Vishal, Kothari, Sneha, Guntur, Saimala, Joshi, Shilpa, Singal, Arbinder
• Format: Journal Article
• Language: English
• Published: New Delhi Springer India 01.06.2023; Springer Nature B.V
• Subjects: Blood glucose; Diabetes; Diabetes mellitus (non-insulin dependent); Family Medicine; General Practice; Glucose; Glucose monitoring; Health Administration; Lifestyles; Medicine; Medicine & Public Health; Original; Original Article; Continuous glucose monitoring; Diabetes; Digital therapeutics; Personalized glycemic response
• ISSN: 0973-3930; 1998-3832
• DOI: 10.1007/s13410-022-01111-1

Background Lifestyle modification is an integral aspect for the management of type 2 diabetes (T2D). However, it is difficult to ensure the accuracy of personalized lifestyle advice. The study aims to analyse the real-world effectiveness of personalized glycemic response based Diabefly-Pro digital therapeutics for better glycemic control. Methods Data from continuous glucose monitoring (CGM) of 64 participants with T2D was analysed. All participants were provided with modified lifestyle plan based on their personalized glycemic response. The CGM data was analysed for a period of 7 days, before and after the introduction of modified lifestyle plan. Primary outcome of the study was change in time in range (TIR). Secondary outcomes of the study were change in mean blood glucose, time above range (TAR), time below range (TBR) and glucose management indicator (GMI). Results Significant improvement in glycemic control was observed after the introduction of personalized lifestyle plan. Median reduction in mean blood glucose was from 139.5 (118.3 to 169.3) mg/dL to 122.0 (101.5 to 148.8) mg/dL ( p < 0.0001). TIR and GMI improved from 70.50 (50.75 to 83.50) % to 75.00 (58.25 to 89.00) % ( p = 0.0001) and 6.64 (6.13 to 7.35) % to 6.23 (5.74 to 6.86) % ( p < 0.0001) respectively. TAR reduced significantly from 17.00 (4.25 to 38.0) % to 6.00 (1.25 to 26.0) % ( p < 0.0001). No significant increase in TBR was observed ( p = 0.198). Conclusion Personalized glycemic response-based Diabefly-Pro digital therapeutics program was effective in achieving better glycemic control in people with T2D.